USD
+0.00
(+0.00%
)AT CLOSE (AS OF Aug 15, 2025)
$2.9B
MARKET CAP
28.6
P/E Ratio
0.81
EPS
$24
52 Week High
$7.3
52 Week Low
LIFE SCIENCES
Sector
Automate your trading workflow with powerful tools — built for serious traders.
Field | Value (USD) |
---|---|
Gross Profit | $957M |
Total Revenue | $1.2B |
Cost Of Revenue | $231M |
Costof Goods And Services Sold | $231M |
Operating Income | $32M |
Selling General And Administrative | $363M |
Research And Development | $107M |
Operating Expenses | $925M |
Investment Income Net | - |
Net Interest Income | -$18M |
Interest Income | $23M |
Interest Expense | $41M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $29M |
Income Before Tax | $14M |
Income Tax Expense | $11M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $3M |
Comprehensive Income Net Of Tax | - |
Ebit | $55M |
Ebitda | $84M |
Net Income | $2M |
Field | Value (USD) |
---|---|
Total Assets | $1.3B |
Total Current Assets | $839M |
Cash And Cash Equivalents At Carrying Value | $319M |
Cash And Short Term Investments | $319M |
Inventory | $178M |
Current Net Receivables | $254M |
Total Non Current Assets | $480M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $5M |
Intangible Assets Excluding Goodwill | $5M |
Goodwill | $2M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $1M |
Other Current Assets | $53M |
Other Non Current Assets | - |
Total Liabilities | $1.7B |
Total Current Liabilities | $939M |
Current Accounts Payable | $63M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $28M |
Total Non Current Liabilities | $728M |
Capital Lease Obligations | $42M |
Long Term Debt | $315M |
Current Long Term Debt | $18M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $375M |
Other Current Liabilities | $841M |
Other Non Current Liabilities | $16M |
Total Shareholder Equity | -$348M |
Treasury Stock | - |
Retained Earnings | -$454M |
Common Stock | $62M |
Common Stock Shares Outstanding | $133M |
Field | Value (USD) |
---|---|
Operating Cashflow | $36M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $29M |
Capital Expenditures | $29M |
Change In Receivables | - |
Change In Inventory | -$45M |
Profit Loss | - |
Cashflow From Investment | $69M |
Cashflow From Financing | -$102M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$173M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $2M |
Field | Value (USD) |
---|---|
Gross Profit | $957M |
Total Revenue | $1.2B |
Cost Of Revenue | $231M |
Costof Goods And Services Sold | $231M |
Operating Income | $32M |
Selling General And Administrative | $363M |
Research And Development | $107M |
Operating Expenses | $925M |
Investment Income Net | - |
Net Interest Income | -$18M |
Interest Income | $23M |
Interest Expense | $41M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $29M |
Income Before Tax | $14M |
Income Tax Expense | $11M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $3M |
Comprehensive Income Net Of Tax | - |
Ebit | $55M |
Ebitda | $84M |
Net Income | $2M |
Field | Value |
---|---|
Ex Dividend Date | 2016-06-16 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.095 |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.